TScan Therapeutics Plans 30% Workforce Cut, FDA Agrees Pivotal Study Design

TScan Therapeutics announced a strategic shift to prioritize its hematologic malignancies program, particularly focusing on the TSC-101 pivotal trial for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), following a positive End-of-Phase 1 meeting with the FDA that aligned on the pivotal study design. The company has paused enrollment in its solid tumor Phase 1 trial to concentrate on clinical development of its hematologic program and preclinical research for in vivo-engineered TCR-T therapies for solid tumors and autoimmunity target discovery. As part of this strategic reprioritization, TScan implemented a workforce reduction of approximately 30%, or 66 employees, aiming to save $45 million annually in 2026 and 2027 and extend its cash runway into the second half of 2027. The pivotal study design will mirror the ongoing Phase 1 study, using a biologically assigned internal control arm to support relapse-free survival as the primary endpoint. The company plans a data readout in the first quarter of 2026 and has scheduled a conference call and webcast to discuss these updates. Overall, the strategic focus, FDA alignment, and financial measures underscore TScan's commitment to advancing its hematologic malignancies program while managing resources effectively.